rethinkPeptides Search
Menu
Study breakdown

CCK and Gastrin Peptides in Human Digestive Diseases: From Gallstones to Gut Cancer

ReviewModerate evidence
The takeaway

CCK and gastrin-related peptides and their receptors play roles in multiple GI diseases including gallbladder dysfunction, pancreatic disorders, and potentially gastrointestinal cancers.

Peptides in GI disease

CCK receptor dysfunction drives gallbladder and pancreatic disease, while gastrin receptors may contribute to GI cancer — peptide targets for common conditions

What the researchers found

CCK/CCK-A receptor dysfunction is implicated in gallbladder and pancreatic diseases, while gastrin/CCK-B receptor abnormalities may contribute to GI cancer development, positioning these peptide systems as therapeutic targets.

Why it matters

GI diseases are extremely common. Understanding the peptide signaling dysfunction underlying them could enable targeted treatments that address root causes rather than symptoms.

How the study worked

Review of clinical and experimental evidence for CCK, gastrin, and their receptor roles across GI diseases including biliary, pancreatic, and neoplastic conditions.

What this study cannot tell us

Review with varying evidence levels across diseases. The causal role of peptide receptor dysfunction versus being a consequence of disease is not always clear.

How to read the evidence

Moderate evidence from a review synthesizing clinical and experimental data across multiple GI disease categories.

When this study was published

Published in 2002. CCK and gastrin biology in GI disease continues to inform drug development and cancer screening.

The bigger picture

Gut peptide signaling disorders may underlie many common digestive diseases. Moving from symptom management to peptide-targeted therapy represents a paradigm shift in gastroenterology.

Questions still open

  • Can CCK agonists treat gallbladder motility disorders?
  • Should gastrin receptor status guide GI cancer screening?
  • Could CCK receptor modulators prevent certain GI cancers?

Common questions

Do gut peptides cause digestive diseases?
They can contribute. CCK receptor dysfunction can impair gallbladder emptying (leading to gallstones) and pancreatic function. Gastrin receptor abnormalities may promote certain GI cancers.
Could targeting these peptides treat disease?
Yes. CCK receptor drugs could treat gallbladder motility problems, and gastrin receptor monitoring could guide cancer screening. These are active areas of GI drug development.

Read the original research

Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders.

Pharmacology & toxicology, 91(6), 333-50

Citation

Jensen, Robert T. (2002). Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders.. Pharmacology & toxicology, 91(6), 333-50.